For UK HealthTech companies
Your product solves a real problem, but NHS decision-makers aren't buying it
Commissioners, procurement leads, and clinical directors each need a different case made to them. Feature-led messaging fails all three, and every month without alignment can defer a substantial sum in contracted revenue.
Two minutes. Solva follows up with specific persona messaging options.
NHS England's 2024 Innovation Adoption report found that 68% of healthtech pilots fail to scale not because of product quality but because of poor stakeholder alignment and unclear value communication.
Frequently asked questions
Why does this problem persist?
Healthtech founders typically come from clinical or technical backgrounds and default to feature-led messaging. NHS decision-makers - ICB leads, procurement, clinical directors - each need a different value narrative. A single product description satisfies none of them.
What is the cost of leaving it unaddressed?
Without persona-specific messaging, your sales cycle extends by months and pilots stall at the point of business case approval. Each delayed contract costs an average £80,000–£200,000 in deferred ARR for a mid-stage healthtech. (NHS England, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.